SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending after halting its compounded weight-loss pill offering due to regulatory pressure, sparking widespread community debate over potential short squeezes, management's competence, and the long-term outlook for its diverse telehealth platform despite a recent Super Bowl ad.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is drawing intense attention following a substantial financing amendment that extends its capital runway through 2028, alongside a new collaboration in cotton traceability. This has fueled a sharp divide among traders, with many anticipating a major short squeeze and a repeat of its history of massive price surges, while others warn of a 'dilution machine' and typical crashes after such momentum.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending with high anticipation for its upcoming Q4 earnings report, as investors weigh its AI-driven, capital-light model against broader fintech sector headwinds and perceived market manipulation. The community is actively discussing the stock's significant undervaluation and potential for a short squeeze, even as some express caution regarding historical post-earnings volatility.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending due to widespread anticipation surrounding a potential POSCO partnership and forthcoming Q4 earnings, with the community actively debating the implications of a recent share dilution and robust HRC prices amidst high short interest. Many speculate on a significant upside driven by these catalysts and supportive tariffs.

Edgewell Personal Care Co. engages in the manufacturing and marketing of personal care products. It operates through the following segments: Wet Shave, Sun and Skin Care, and Feminine Care. The Wet Shave segment involves Schick, Wilkinson Sword, edge, Skintimate, Billie, and Shave Guard. The Sun and Skin Care segment consists of Banana Boat, Hawaiian Tropic, and Wet Ones. The Feminine Care segment refers to Playtex, Stayfree, and Carefree. The company was founded on September 23, 1999 and is headquartered in Shelton, CT.

Edgewell Personal Care Co

Edgewell Personal Care is trending following its recent Q1 '26 earnings, which reported a decline in GAAP EPS and revenue, coupled with a revised fiscal 2026 outlook reflecting the divestiture of its feminine care business. The community is actively discussing ongoing operational credibility concerns, profitability challenges in a competitive consumer market, and renewed speculation surrounding potential strategic moves or a company buyout.

The Kroger Co. engages in the retail grocery business with added convenience to retail pharmacies and fuel centers. Its main focus is on growing households and increasing customer loyalty by delivering great value and convenience, and investing in four strategic pillars: Fresh, Brands, Data & Personalization and Seamless. Its brands include Big K, Smart Way, Heritage Farm, Simple Truth, and Simple Truth Organic. The company was founded by Barney Kroger in 1883 and is headquartered in Cincinnati, OH.

Kroger Co.

Kroger is trending as investors rally behind reports of retail veteran Greg Foran, former Walmart U.S. CEO, taking the helm, seeing his proven operational expertise as key to a fresh strategy in the highly competitive grocery market.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is a focal point as its strategic acquisition in physical AI sensing, strong revenue growth, and robust balance sheet bolster its leadership within a consolidating lidar market. The community is actively debating its diversified impact across robotics and smart infrastructure, increasingly viewing it as a foundational technology for the expanding physical AI revolution.

Arbor Realty Trust, Inc. operates as a real estate investment trust, which engages in the provision of loan origination and servicing for multifamily, seniors housing, healthcare, and diverse commercial real estate assets. It operates through the Structured Business and Agency Business segments. The Structured Business segment offers a diversified portfolio of structured finance assets in the multifamily, single-family rental, and commercial real estate markets. The Agency Business segment focuses on the sale and service of a range of multifamily finance products through the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation. The company was founded by Ivan Kaufman in June 2003 and is headquartered in Uniondale, NY.

Arbor Realty Trust Inc.

Arbor Realty Trust is trending due to a recent credit rating upgrade and significant insider buying, as the community actively debates whether anticipated interest rate cuts will trigger a short squeeze in the heavily-shorted mortgage REIT.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the inauguration of its Eagle Line pilot production facility, signaling a crucial transition from R&D to scalable manufacturing, which is fueling community speculation about new OEM partnerships and its disruptive potential ahead of upcoming earnings.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co.

Becton, Dickinson And Co.

BDX is trending due to a strong Q1'26 earnings beat and reaffirmed guidance, alongside significant strategic portfolio shifts. Investors are closely watching the imminent completion of the Biosciences unit's merger with Waters Corp and the recent acquisition of Edwards Lifesciences' Critical Care group, which aim to propel the company into focused growth areas like advanced diagnostics and connected care.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioXcel Files SNDA To Expand IGALMI Label For At-Home Setting

(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) said on Tuesday that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for IGALMI, seeking approval...

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If...

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BioXcel Therapeutics, Inc. (BTAI) announced on Wednesday that its BXCL501 demonstrated continued effects and consistent benefit with repeat dosing in the treatment of agitation associated with bipolar disorders or schizophrenia in a late-stage trial.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine, marketed by the company as Igalmi. While the primary objective of the trial was to ascertain the safety of the formulation in an at-home setting, the continued effects and consistent benefits observed with repeat dosing in the trial further support the potential of BXCL501 for use in the outpatient setting, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-positive-topline-exploratory">said</a>.Shares of the company rose 3% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.BioXcel <a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-sublingual-film-well-tolerated-in-bipolar-schizophrenia-trial-in-at-home-settings/chsU5sURdl5">reported</a> late last month that the drug was well-tolerated in the study. The company said that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration (FDA) slated for the first quarter of 2026 and aimed at expanding the label for Dexmedetomidine in the at-home setting.“These positive results, along with the safety and tolerability data previously announced, reinforce BXCL501’s potential in the at-home setting where there is substantial unmet need with no FDA-approved options currently available,” said BioXcel CEO Vimal Mehta.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.BTAI stock is down by 40% this year and by 59% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-ahead-of-inflation-data/chwkJpfRduc">Dow Futures Edge Lower As Investors Turn Cautious Ahead Of Inflation Data: ORCL, KLAR, HOOD, GME Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study

The company stated that the continued effects and consistent benefits observed with repeat dosing in the trial support the potential of BXCL501 for use in the outpatient setting. 

Equity

BioXcel Therapeutics, Inc. (BTAI) on Wednesday said that its late-stage trial evaluating the safety of the company’s BXCL501 as a treatment for agitation associated with bipolar disorders or schizophrenia in the at-home setting met its primary goal of being well-tolerated.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-serenity-home-pivotal-phase-3">said</a> that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration slated for the first quarter of 2026 and aimed at expanding the label for its dexmedetomidine sublingual film called Igalmi in the at-home setting.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_9_42_20_AM_png_54402b6e8c.webp" alt="BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="624" height="65"><figcaption>BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the shares of the company.<stembedurl>https://stocktwits.com/Michael17711771/message/626688937</stembedurl>Another user opined that the study results are very promising long term.<stembedurl>https://stocktwits.com/They_call_me_tater_salad/message/626688733</stembedurl>BioXcel said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.“By meeting its primary endpoint, the SERENITY At-Home Pivotal Phase 3 trial reinforces BXCL501’s potential to be safely used at home like it is already used in the previously FDA approved institutional setting. The unmet medical need in the at-home setting is significant with no FDA-approved treatments,” CEO Vimal Mehta said, while adding that the company believes the total addressable market is “significantly larger” than previously reported.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.The company said that available data demonstrate that treatment with BXCL501 regularly reduced symptoms of agitation throughout the trial. A greater percentage of patients experiencing mild, moderate, or severe agitation had full resolution of symptoms in the BXCL501 arm compared with placebo. Complete analyses of the full data set are ongoing and will be shared in time, the company said.BTAI stock is down by 24% this year and by 57% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later

The company said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.

BioXcel Therapeutics drew sharp retail-trader attention early Wednesday as the company gears up to release topline results later in the day for its experimental therapy to treat agitation linked to bipolar disorders and schizophrenia outside of clinical settings.The report from its SERENITY At-Home Phase 3 safety trial will reveal detailed effects of BXCL501, marketed as Igalmi, the company's sublingual film formulation of dexmedetomidine. The company plans to hold an investor call and webcast at 8 a.m. ET to discuss the data.The announcement about the release, made late Tuesday, triggered a 19% spike in&nbsp;<a href="https://stocktwits.com/symbol/BTAI">BioXcel's stock</a> after the bell, sending the ticker to the top of trending symbols on Stocktwits, accompanied by a 118% surge in 24-hour message volume. Sentiment, however, was ‘neutral’ as of the last reading.<figure class="image"><img style="aspect-ratio:1310/194;" src="https://news.stocktwits-cdn.com/BTAI_stock_sentiment_and_message_volume_on_Aug_27_png_6d08b1cb22.webp" alt="BTAI stock sentiment and message volume on Aug 27.png" width="1310" height="194"><figcaption>BTAI stock sentiment and message volume on Aug 27 as of 3:30 am ET | source: Stocktwits</figcaption></figure>Last week, BioXcel captured investors' attention after the company<a href="https://stocktwits.com/news-articles/markets/equity/bio-xcel-stock-in-focus-fda-issues-positive-early-feedback-ahead-of-key-meeting-on-expanded-psychiatric-label-1/chsOR5KRdQ1">&nbsp;said</a> the FDA had provided positive preliminary comments for Igalmi.The trial enrolled 200 patients living with bipolar disorder or schizophrenia who experienced agitation episodes despite being on stable treatment. Over 12 weeks, participants self-administered either 120 mcg of BXCL501, the same dose approved under medical supervision, or a placebo when symptoms arose.The trial tracked adverse events as its primary safety endpoint, while patients or caregivers also provided feedback using a modified global impression of severity scale.Igalmi is also being studied for agitation associated with Alzheimer's dementia, bipolar disorder, and schizophrenia in outpatient and at-home settings. It has received an FDA breakthrough therapy designation for agitation linked to dementia and a fast-track designation for agitation tied to schizophrenia, bipolar disorders, and dementia.BioXcel's stock short interest has also plunged since March, from over 10.6% to 1.8% as of the end of last week, according to Koyfin data.Shares of the company have shed nearly 15% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/firefly-neuroscience-stock-scores-biggest-gain-in-weeks-on-nvidia-brain-platform-boost/chsxnkFRdkQ">Firefly Neuroscience Stock Scores Biggest Gain In Weeks On Nvidia Brain Platform Boost</a>

BioXcel's trial enrolled 200 patients living with bipolar disorder or schizophrenia who experienced agitation episodes despite being on stable treatment. | Representative image via Getty Images

BioXcel Sparks Retail Frenzy As Stock Soars Ahead Of Phase 3 Results For Bipolar, Schizophrenia Drug

Shares surged after hours on Tuesday, making BioXcel the most talked-about stock on Stocktwits, with message volume up 118% in the 24 hours following the announcement.

All Eyes On BioXcel Stock As Phase 3 Data For Bipolar, Schizophrenia Drug Due Today

Shares surged after hours on Tuesday, making BioXcel the most talked-about stock on Stocktwits, with message volume up 118% in the 24 hours following the announcement.


Retail chatter surged around BioXcel Therapeutics early Monday after the company said it received positive preliminary FDA comments ahead of an&nbsp;Aug. 20&nbsp;meeting to discuss expanding Igalmi’s label for at-home use in agitation tied to bipolar disorder and schizophrenia.The FDA’s remarks focused on aligning with the company over the format and content of the upcoming&nbsp;supplemental new drug application (sNDA)&nbsp;submission. BioXcel said it is evaluating the comments and expects to provide an update following the meeting.&nbsp;Currently, Igalmi is approved for hospital or supervised clinical use, and a green light for outpatient administration would open a new, significantly larger commercial opportunity.The regulatory update comes on the heels of BioXcel completing its Serenity At-Home Phase 3 trial earlier this month, with&nbsp;the&nbsp;last patient visits finalized across 22 U.S. sites.&nbsp;The pivotal study enrolled more than 200 patients and is designed to assess the safety of a 120 mcg self-administered dose of BXCL501 for acute agitation episodes in home settings. Top-line data are expected later this quarter and will form the backbone of the planned sNDA filing.The FDA has previously granted BXCL501 Breakthrough Therapy designation for dementia-related agitation and Fast Track status for schizophrenia, bipolar disorder, and dementia.&nbsp;BioXcel has also received two favorable recommendations from its Data Safety Monitoring Board, supporting the drug’s advancement toward regulatory review.Last Friday, H.C. Wainwright boosted its price target on the stock to $10 from $8 while sticking with a Buy rating, pointing to growing excitement around BXCL501.&nbsp;The brokerage firm called the upcoming Serenity trial readout “low-risk” and expects the company&nbsp;to&nbsp;file for an expanded label by the end of the year, with the FDA potentially signing off in the second half of 2026.On Aug. 6, BioXcel said a new paper in Frontiers in Pharmacology highlighted dexmedetomidine, the key ingredient in BXCL501.The study showed it could significantly influence stress-related behaviors in preclinical models, raising the possibility that the drug’s use might extend beyond calming acute agitation to helping manage longer-term psychiatric conditions.On Stocktwits, retail sentiment for BioXcel was described as ‘extremely bullish’ with ‘extremely high’ message volume, making it the platform’s most trending stock.One user urged that “$BTAI could be pushed over $50 this week” if investors “stick together,” adding that the community had the power to make it happen.&nbsp;<stembedurl>https://stocktwits.com/Eastcoasttrader11/message/625574895</stembedurl>Another user noted that if the Aug. 20 meeting went positively, it would signal that Phase 3 data had already come back strong as expected.<stembedurl>https://stocktwits.com/PejalPapa/message/625574210</stembedurl><a href="https://stocktwits.com/symbol/BTAI">BioXcel’s stock</a> has declined 8.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter surged around BioXcel Therapeutics (BTAI) early Monday after the company said it received positive preliminary FDA comments. (Photo credit: Getty Images)

BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label 

The update comes as the company wraps up its pivotal Serenity At-Home Phase 3 trial and analysts grow more optimistic on BXCL501’s commercial potential. 

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

BioXcel Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Current Price	$1.50
Prev Close	$1.37
Open	$1.38
Dividend Yield	0.00%
50-Day Moving Average	$1.84
Beta	1.44
Avg. Volume	643,227.95
PE Ratio	-0.15

52-Week High	$8.08
52-Week Low	$1.17
Market Capitalization	$32.8M
EPS (Annual)	-$23.51
Price to Book	-0.34
Revenue Per Employee	$61,243.24
Enterprise Value/EBITDA	N/A

BTAI
BioXcel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BTAI News

BTAIBioXcel Therapeutics Inc